Close Menu

Making RNAi work in therapeutic application is tricky, and here, Derek Lowe reports on a paper published in Nature last week that does a good job demonstrating just how much researchers don't know. They used RNAi to knock down VEGF, whose overactivation leads to macular degeneration.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.